- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Belzutifan is the first approved HIF-2 α inhibitor for the treatment of VHL syndrome associated renal cell carcinoma, exerting anti-tumor effec...
Welireg, as the first approved HIF-2 α inhibitor for the treatment of VHL syndrome associated renal cell carcinoma, has shown significant tumor...
When Belzutifan is used to treat VHL related tumors, it is important to focus on managing common adverse reactions such as anemia, hypoxia, and...
Belzutifan is a novel HIF-2 α inhibitor that provides a new targeted therapy option for patients with inoperable VHL related tumors. This drug ...
Glasdegib tablets combined with low-dose cytarabine is a standardized regimen for the treatment of newly diagnosed acute myeloid leukemia (AML)...
Glasdegib film is a targeted drug used to treat newly diagnosed acute myeloid leukemia (AML), which requires combination with low-dose cytarabi...
The side effects of Tasfigo succinate involve multiple systemic reactions and require differentiated management measures based on severity. The...
Tasfigo succinate is a novel tyrosine kinase inhibitor that exerts anti-tumor effects by targeting FGFR1/2/3, mainly used for the treatment of ...
Tasfigo succinate is an anti-tumor drug targeting FGFR1/2/3, mainly used to treat biliary cancer patients with FGFR2 gene abnormalities. The fo...
Betamethasone, as an ATP citrate lyase inhibitor, significantly reduces LDL-C levels by blocking the upstream pathway of cholesterol synthesis,...
